Home › Compare › WDGJF vs ABBV
WDGJF yields 512.82% · ABBV yields 3.06%● Live data
📍 WDGJF pulled ahead of the other in Year 1
Combined, WDGJF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WDGJF + ABBV for your $10,000?
John Wood Group PLC, together with its subsidiaries, provides consulting, project management, and engineering solutions to energy and built environment worldwide. It operates through four segments: Projects, Operations, Consulting, and Investment. The company offers engineering solutions, including decarbonization and optimization in energy and industry; and renewable energy, future fuels, and low carbon solutions. It also provides environment and infrastructure solutions comprising environmental studies and compliance, environmental remediation, public infrastructure, and geotechnical and materials services; clean energy solutions; mine planning and design, mineral processing and metallurgy, mineral resources and project assessment services; and automation and control solutions, such as asset protection and facility and process automation solutions, as well as simulation, learning, and virtual systems. In addition, the company offers subsea and export systems, including subsea, umbilical, riser, and flowline design, as well as planning, design, and development of marine terminals and pipelines; and hull and marine services. It serves oil and gas, infrastructure, industrial and manufacturing, mining, power, and government sectors. John Wood Group PLC was incorporated in 1961 and is headquartered in Aberdeen, the United Kingdom.
Full WDGJF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.